List of Excipients in Branded Drug CHILDRENS WAL-ITIN

Generic Drugs Containing CHILDRENS WAL-ITIN

Company	Ingredient	NDC	Excipient
Walgreen Company	loratadine	0363-2092	GLYCERIN
Walgreen Company	loratadine	0363-2092	PHOSPHORIC ACID
Walgreen Company	loratadine	0363-2092	POLYETHYLENE GLYCOLS
Walgreen Company	loratadine	0363-2092	PROPYLENE GLYCOL
Walgreen Company	loratadine	0363-2092	SODIUM BENZOATE
Walgreen Company	loratadine	0363-2092	SODIUM METABISULFITE

What are the Most Frequently-Used Excipients in CHILDRENS WAL-ITIN?

# Of NDCs	Excipient
1	GLYCERIN
1	PHOSPHORIC ACID
1	POLYETHYLENE GLYCOLS
1	PROPYLENE GLYCOL
1	SODIUM BENZOATE
1	SODIUM METABISULFITE

Children's Wal-Itin Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Children's Wal-Itin is an over-the-counter loratadine product for pediatric allergy relief. The commercial opportunity is not based on active-ingredient exclusivity. Loratadine is an established, multisource antihistamine. Value is concentrated in palatability, dosing accuracy, preservative and allergen positioning, packaging, retailer distribution, and cost control.

The most commercially relevant format is loratadine oral solution at 5 mg per 5 mL for children age 2 years and older. Public labeling identifies the product as an oral liquid containing loratadine, with inactive ingredients used to provide sweetness, flavor, viscosity, pH control, preservation, and physical stability.[1] Exact excipient composition can vary by product presentation and manufacturing source, so commercial decisions should be based on the current package insert and Drug Facts label.

What is Children's Wal-Itin and who markets it?

Children's Wal-Itin is a store-brand pediatric allergy medicine associated with the Walgreens retail channel. The active ingredient is loratadine, a second-generation H1 antihistamine indicated for temporary relief of symptoms associated with hay fever or other upper respiratory allergies, including sneezing, runny nose, itchy nose or throat, and itchy or watery eyes.[1]

Attribute	Product profile
Product	Children's Wal-Itin
Active ingredient	Loratadine
Dosage form	Oral solution or liquid presentation
Typical strength	5 mg per 5 mL
OTC status	Nonprescription
Pediatric labeling	Children age 2 years and older, subject to label directions
Therapeutic class	Second-generation antihistamine
Primary competitors	Claritin, generic loratadine, Children's Zyrtec, Children's Allegra, store-brand equivalents
Commercial channel	Retail pharmacy, mass retail, e-commerce, private label
Patent position	No meaningful brand-specific composition exclusivity publicly evident for the established loratadine OTC product

The product is regulated under the FDA's OTC antihistamine framework rather than as a novel prescription medicine.[2] A specific product may also be supported by an FDA-approved OTC application or a monograph-compliant pathway, depending on its regulatory history and formulation.

What excipients are used in Children's Wal-Itin?

The excipient system for a pediatric loratadine liquid normally has six functional objectives:

1. Dissolve or uniformly disperse loratadine.
2. Deliver an acceptable taste and mouthfeel.
3. Maintain chemical and physical stability.
4. Prevent microbial growth after opening.
5. Provide accurate dosing through a calibrated device.
6. Support low-cost, high-volume manufacturing.

Public labeling for Children's Wal-Itin identifies inactive ingredients, but the formulation should not be treated as interchangeable with every other loratadine liquid. Product-specific excipient differences can affect taste, viscosity, preservative performance, compatibility with packaging, and consumer tolerability.[1]

Excipient functions and commercial implications

Excipient function	Common formulation approach	Commercial relevance
Vehicle	Purified water	Lowest-cost primary solvent and standard pediatric liquid vehicle
Sweetening	Sugar, sorbitol, sucralose, or combinations	Determines taste, caloric content, dental positioning, and gastrointestinal tolerability
Flavor	Fruit flavor, often grape or similar pediatric profile	Major purchase and repeat-use driver
Buffer or pH adjuster	Citrate, phosphate, or related system	Controls stability and preservative performance
Preservative	Parabens, benzoate, sorbate, or another permitted system	Supports multidose shelf life after opening
Viscosity modifier	Cellulose derivative, xanthan gum, or related polymer	Reduces settling, improves mouthfeel, and supports dose uniformity
Solubilizer or surfactant	Product-dependent	Helps maintain a uniform liquid and may affect taste or foam
Coloring agent	Product-dependent	Supports product identification but creates dye-sensitive consumer concerns
Chelating agent	Product-dependent	Can improve stability by binding trace metals
pH modifier	Citric acid, sodium citrate, or equivalent	Controls pH and taste

The highest-value excipient decisions are usually flavor, sweetener, preservative, color, and viscosity. These components directly affect caregiver acceptance and product differentiation. Loratadine itself is a mature active ingredient with limited ability to distinguish a store-brand product.

What excipient strategy is best for a pediatric loratadine liquid?

A commercially strong formulation should prioritize taste, dosing reliability, preservative robustness, and broad consumer acceptability.

Taste and palatability

Pediatric antihistamine liquids compete heavily on taste. Loratadine has limited intrinsic solubility and may require a solubilization approach that creates bitterness or lingering aftertaste. Flavor masking should be evaluated under realistic conditions:

• Immediate taste after administration.
• Aftertaste at 5 to 15 minutes.
• Taste after repeated daily dosing.
• Performance when taken with food.
• Acceptance by children in different age groups.

A grape profile is commercially familiar in pediatric medicines, but fruit-flavor selection should be tested against competing products. A milder berry or mixed-fruit profile could support premium positioning if it produces better masking without increasing flavor load.

Sugar-free positioning

A sugar-free formulation can broaden use among caregivers seeking lower-calorie products and may reduce concerns about dental exposure. Sorbitol and other polyols require gastrointestinal tolerability assessment, particularly at repeated pediatric doses. High polyol levels can create laxation warnings or poor consumer acceptance.

High-intensity sweeteners can reduce calories and viscosity requirements, but they may leave a bitter or metallic aftertaste. A blended sweetener system often provides a better taste profile than reliance on a single sweetener.

Dye-free positioning

Dye-free labeling can expand appeal among caregivers who avoid artificial colors. The commercial benefit is strongest in e-commerce and pharmacy channels where product attributes can be displayed in search filters and digital listings.

Removing color can reduce visual differentiation on the shelf. Packaging design must then carry the identification burden through large dosage-strength labeling, colored caps, and child-resistant packaging elements.

Preservative strategy

A multidose pediatric liquid requires microbial-control validation throughout the proposed shelf life and in-use period. The selected preservative must remain effective across the formulation's pH range and must be compatible with the bottle, cap, dosing syringe, and flavor system.

Preservative selection is a tradeoff:

• Paraben systems can provide broad antimicrobial performance but may be less attractive for "clean label" positioning.
• Benzoate and sorbate systems can support consumer-friendly claims but are strongly pH-dependent.
• Preservative-free packaging may be possible with unit-dose containers, but the cost and packaging burden are higher.

For a mass-market Walgreens product, a conventional multidose system is generally more commercially efficient than unit-dose packaging unless the product is repositioned for travel, school, or institutional use.

What formulation patents protect Children's Wal-Itin?

No meaningful product-specific formulation patent estate is publicly associated with Children's Wal-Itin based on its established OTC store-brand positioning. Loratadine composition-of-matter protection expired years ago, and the product competes with generic loratadine products.

The likely IP position is therefore narrow:

IP category	Relevance to Children's Wal-Itin
Loratadine compound patents	Expired or commercially irrelevant to current store-brand entry
Original prescription formulation patents	Generally expired and not a barrier to OTC private-label competition
Product-specific excipient patents	No material public estate identified
Method-of-use patents	Limited relevance for standard OTC allergy indications
Manufacturing know-how	Potentially important but usually confidential
Trademark and trade dress	Commercially relevant to the Wal-Itin brand
Packaging configuration	May be protectable, but unlikely to create a substantial market barrier
Regulatory exclusivity	No apparent current exclusivity for the mature OTC product

A differentiated excipient system could create trade-secret value, but it would not ordinarily provide strong exclusion comparable to a granted formulation patent. The most defensible commercial assets are validated taste systems, stability data, supplier relationships, and packaging execution.

What is the FDA regulatory status of Children's Wal-Itin?

Loratadine is an FDA-recognized OTC antihistamine active ingredient. FDA's OTC antihistamine framework addresses active ingredients, indications, warnings, dosage, and labeling requirements.[2] The product must also comply with current good manufacturing practice requirements, including identity, strength, quality, purity, packaging, and testing controls.[3]

Pediatric liquid development must address:

• Age-appropriate dosing.
• Dose-volume accuracy.
• Child-resistant packaging.
• Label comprehension.
• Microbial limits and preservative effectiveness.
• Stability under labeled storage conditions.
• Container-closure compatibility.
• Appropriate allergen and excipient declarations.
• Controls for manufacturing cross-contamination.

A formulation change involving flavor, preservative, sweetener, color, or viscosity can require regulatory assessment even when the active ingredient and labeled indication remain unchanged. The commercial objective should be to establish a change-control strategy that permits future excipient sourcing changes without unnecessary product disruption.

When does Children's Wal-Itin lose exclusivity?

Children's Wal-Itin has no apparent market exclusivity tied to a novel active ingredient. Generic loratadine products and competing store brands can enter without waiting for expiration of a current compound patent. The product's competitive protection comes from retail placement, private-label contracting, brand recognition, price, and consumer experience.

There is no conventional Orange Book patent barrier comparable to a recently approved prescription product. A standard abbreviated new drug application Paragraph IV challenge is therefore not the principal competitive risk. A competing manufacturer can generally commercialize loratadine oral liquid if it satisfies FDA requirements and avoids protected trademarks or a still-valid, product-specific patent.

Orange Book status

The Orange Book primarily identifies approved prescription drug products and associated patent and exclusivity information. A mature OTC store-brand loratadine product should not be analyzed as an Orange Book-protected brand in the same way as a patented prescription medicine.[4]

The relevant legal risks are more likely to involve:

• Trademark infringement.
• False or misleading comparative claims.
• Packaging or trade-dress disputes.
• Contract manufacturing restrictions.
• Confidential formulation know-how.
• Product-liability exposure.
• FDA compliance issues.

What generic entry risks exist for Children's Wal-Itin?

Generic and private-label entry risk is high because:

1. Loratadine is widely available.
2. The active ingredient is low cost.
3. The dosage form is technically established.
4. The product is sold through multiple retail channels.
5. Caregivers can readily substitute among equivalent allergy medicines.
6. Retailers can dual-source or rebrand the product.

The principal barriers are operational rather than patent-based. A competitor must achieve acceptable taste, stable preservative performance, reliable dose delivery, and a competitive landed cost.

Generic launch scenarios

Scenario	Probability profile	Commercial effect
Lower-priced loratadine liquid	High	Direct price pressure and retailer margin compression
Dye-free or sugar-free competitor	Medium to high	Captures health-conscious caregivers
Better-tasting competitor	Medium	Increases switching and repeat-purchase risk
Single-dose stick or sachet	Low to medium	Creates convenience differentiation
Loratadine chewable or dissolving tablet	High	Substitutes for liquid use in older children
Cetirizine or fexofenadine alternative	High	Therapeutic substitution, particularly where caregivers perceive longer or stronger relief
Premium organic-positioned product	Low to medium	Small but potentially higher-margin niche

How strong is the patent estate for Children's Wal-Itin?

The patent estate is weak as a source of exclusivity. The product's defensibility is better described as commercial and operational.

Defensibility factor	Assessment
Active-ingredient patent	Weak or expired
Formulation patent	No material public protection identified
Method-of-use patent	Weak for standard allergy indications
Brand recognition	Moderate within the retail channel
Retail distribution	Potentially strong if supported by preferred placement
Cost position	Potentially strong through private-label scale
Taste differentiation	Variable and testable
Manufacturing know-how	Potentially meaningful
Switching costs	Low
Substitute products	Numerous

A retailer can strengthen the product's position through exclusive flavor profiles, differentiated package sizes, subscription sales, and coordinated seasonal inventory. These measures do not block entry, but they can improve shelf productivity and reduce direct price comparison.

What commercial opportunities exist for excipient innovation?

The strongest opportunities are incremental rather than patent-led.

Sugar-free, dye-free pediatric liquid

A combined sugar-free and dye-free product can target caregivers seeking fewer inactive ingredients. The formulation must preserve taste and mouthfeel while avoiding an excessive sweetener or preservative burden.

Low-volume concentrated dose

A more concentrated formulation could reduce dosing volume, improve portability, and lower packaging material per dose. It would require careful pediatric safety controls because concentration errors can materially increase overdose risk. A concentration change would also require clear labeling and dose-device validation.

Premium taste system

A taste-masked formulation with reduced bitterness and improved aftertaste could support a premium store-brand tier. Consumer testing should compare the product directly with Children's Claritin and generic loratadine liquids rather than relying on adult sensory panels.

Unit-dose packaging

Unit-dose cups, sachets, or oral syringes could address school, travel, and caregiver convenience. The disadvantage is higher packaging cost and greater material use. This format is more likely to work as a niche SKU than as the base mass-market product.

Device-led differentiation

A calibrated oral syringe with a low-dead-space tip can improve dose delivery and reduce caregiver error. A dosing device is more commercially defensible than a minor flavor change because it can improve usability and support stronger product reviews.

What licensing deals and manufacturing barriers matter?

No major public licensing transaction appears central to Children's Wal-Itin. The likely commercial model is retailer private label, contract manufacturing, or a supply agreement with a finished-dose manufacturer.

Manufacturing barriers include:

• Loratadine solubilization and uniformity.
• Flavor and preservative compatibility.
• Bottle and closure adsorption.
• Microbial control during filling and use.
• Stability under heat and cold excursions.
• Reliable supply of pharmaceutical-grade flavors and polymers.
• Seasonal demand volatility during allergy peaks.
• Retailer requirements for rapid replenishment and low defect rates.

A manufacturer with validated pediatric liquid capacity, strong sensory-development capabilities, and flexible packaging lines can compete more effectively than a low-cost solid-dose manufacturer entering the category without liquid expertise.

What patent litigation or settlement agreements affect the product?

No material public patent litigation or Paragraph IV settlement is associated with Children's Wal-Itin as a mature OTC loratadine store-brand product. The absence of patent litigation is consistent with the product's established active ingredient and broad generic availability.

Potential disputes are more likely to involve product quality, labeling, trademarks, retailer contracts, or alleged trade dress than patent validity or infringement.

How does Children's Wal-Itin compare with competing children's allergy products?

Product category	Active ingredient	Main differentiation	Relative threat
Children's loratadine liquid	Loratadine	Low price, non-drowsy positioning, familiar OTC category	Direct
Children's cetirizine liquid	Cetirizine	Strong consumer awareness and broad generic availability	High substitution threat
Children's fexofenadine liquid	Fexofenadine	Non-drowsy positioning and premium perception	Moderate substitution threat
Loratadine chewables	Loratadine	Convenience and no liquid measurement	High for older children
Branded Claritin liquid	Loratadine	Brand recognition and marketing	Moderate to high
Store-brand equivalents	Loratadine	Lower price and retailer access	Direct and severe

The product is most exposed during seasonal allergy periods, when retailers can use price promotions to shift share rapidly. A strong formulation alone will not protect volume if inventory is unavailable during peak demand.

What revenue exposure and opportunity should investors assess?

Standalone Children's Wal-Itin revenue is generally not disclosed by retailers. Exposure should therefore be modeled using category sales, unit velocity, average retail price, seasonal concentration, and retailer gross margin rather than relying on public product-level revenue.

Key commercial variables include:

• Retail price per 5 mL equivalent.
• Bottle size and annual units sold.
• Share of sales during spring and fall allergy seasons.
• Gross margin after contract manufacturing and logistics.
• Promotional discounting.
• E-commerce versus store sales.
• Out-of-stock rate.
• Repeat purchase rate.
• Cannibalization of adult loratadine products.
• Substitution into cetirizine and fexofenadine.

The most attractive opportunity is a differentiated, low-cost pediatric liquid with strong taste performance, clear sugar-free or dye-free positioning, and a dosing device that supports caregiver confidence. Patent-based upside is limited.

Key Takeaways

• Children's Wal-Itin is a mature OTC loratadine product with little apparent patent-based exclusivity.
• Excipient strategy is commercially important because taste, sweetener, preservative, color, and viscosity drive pediatric acceptance.
• The strongest opportunities are sugar-free and dye-free positioning, improved flavor masking, concentrated dosing, unit-dose packaging, and better dosing devices.
• Generic and private-label entry risk is high.
• No material Orange Book, Paragraph IV, patent litigation, or settlement barrier appears central to the product.
• Manufacturing know-how, sensory data, retailer access, supply reliability, and cost control are more valuable than a conventional patent estate.
• Product-level revenue is not publicly disclosed, so commercial analysis should use category, channel, pricing, and seasonal-volume assumptions.

FAQs

Is Children's Wal-Itin the same as Claritin?

Both products may contain loratadine, but excipients, flavor, bottle size, dosing device, manufacturer, and labeling presentation can differ. Therapeutic substitution should be based on the active ingredient, strength, age directions, and FDA-compliant labeling.

Can a company patent a new Children's Wal-Itin flavor?

A flavor change alone may not provide strong patent protection. Patentability would depend on a non-obvious formulation or measurable technical benefit. Trade secrets, trademarks, and commercial branding may provide more practical protection.

Is a sugar-free loratadine liquid commercially attractive?

Yes. Sugar-free positioning can appeal to caregivers seeking lower-calorie products, but the formulation must manage sweetener aftertaste, polyol tolerability, preservative performance, and viscosity.

What is the main technical risk in developing a competing loratadine liquid?

The main risk is achieving acceptable taste while maintaining loratadine uniformity, chemical stability, microbial protection, and dose accuracy across the full shelf life.

Could Children's Wal-Itin be converted to a unit-dose format?

Yes, but unit-dose packaging would increase packaging and filling costs. The strongest target markets would be travel, school, institutional use, and convenience-focused e-commerce rather than the lowest-cost mass-market segment.

References

1. DailyMed. (n.d.). Children's Wal-Itin 24 hour allergy relief: Loratadine oral solution labeling. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2022). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use.
3. U.S. Food and Drug Administration. (2024). Current good manufacturing practice, quality systems, and drug manufacturing requirements.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.